Home > Publications database > Application of the long axial field-of-view PET/CT with low-dose [18F]FDG in melanoma. > print

001     186247
005     20241228120954.0
024 7 _ |a 10.1007/s00259-022-06070-7
|2 doi
024 7 _ |a pmid:36474125
|2 pmid
024 7 _ |a 1619-7070
|2 ISSN
024 7 _ |a 0340-6997
|2 ISSN
024 7 _ |a 1432-105X
|2 ISSN
024 7 _ |a 1619-7089
|2 ISSN
024 7 _ |a altmetric:139890001
|2 altmetric
037 _ _ |a DKFZ-2022-03041
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Sachpekidis, Christos
|0 P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2
|b 0
|e First author
|u dkfz
245 _ _ |a Application of the long axial field-of-view PET/CT with low-dose [18F]FDG in melanoma.
260 _ _ |a Heidelberg [u.a.]
|c 2023
|b Springer-Verl.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1677071903_29372
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:E060#LA:E060# / 2023 Mar;50(4):1158-1167
520 _ _ |a The recent introduction of long axial field-of-view (LAFOV) PET/CT scanners has yielded very promising results regarding image quality and sensitivity in oncological patients. We, herein, aim to determine an appropriate acquisition time range for the new long axial field of view Biograph Vision Quadra PET/CT (Siemens Healthcare) using low dose [18F]FDG activity in a group of melanoma patients.Forty-nine melanoma patients were enrolled in the study. All patients underwent total body PET/CT from the top of the head through the feet in two bed positions (field-of-view 106 cm) after i.v. injection of 2.0 MBq/kg [18F]FDG. The PET images of the first bed position (head to upper thigh; PET-10) were reconstructed and further split into 8-min (PET-8), 6-min (PET-6), 5-min (PET-5), 4-min (PET-4), and 2-min (PET-2) duration groups. Comparisons were performed between the different reconstructed scan times with regard to the visual evaluation of the PET/CT scans using the PET-10 images as reference and by calculating the 95%-CI for the differences between different time acquisitions. Moreover, objective evaluation of PET/CT image quality was performed based on SUV calculations of tumor lesions and background, leading to calculation of liver signal-to-noise ratio (SNR), and tumor-to-background ratio (TBR).A total of 60 scans were evaluated. Concerning visual analysis, 49/60 (81.7%) PET-10 scans were pathological, while the respective frequencies were 49/60 (81.7%) for PET-8 (95%-CI: - 0.0602-0.0602), 49/60 (81.7%) for PET-6 (95%-CI: - 0.0602-0.0602), 48/60 (80%) for PET-5 (95%-CI: - 0.0445-0.0886), 46/60 (76.7%) for PET-4 (95%-CI: - 0.0132-0.1370), and 45/60 (75%) for PET-2 (95%-CI: 0.0025-0.1593). In 18 PET-10 scans, the extent of metastatic involvement was very large, rendering the accurate calculation of [18F]FDG-avid tumor lesions very complicated. In the remaining 42 PET-10 scans, for which the exact calculation of tumor lesions was feasible, a total of 119 tumor lesions were counted, and the respective lesion detection rates for shorter acquisitions were as follows: 97.5% (116/119) for PET-8 (95%-CI: 0-1), 95.0% (113/119) for PET-6 (95%-CI: 0-1), 89.9% (107/119) for PET-5 (95%-CI: 0-2), 83.2% (99/119) for PET-4 (95%-CI: 1-2), and 73.9% (88/119) for PET-2 (95%-CI: 2-4). With regard to objective image quality evaluations, as a general trend, the reduction of acquisition time was associated with a decrease of liver SNR and a decrease of TBR, although in lesion-based analysis the change in TBR and tumor SUVmean values was non-significant up to 6 and 5 min acquisitions, respectively.In melanoma, low-dose LAFOV PET/CT imaging is feasible and can reduce the total scan time from head to upper thigh up to 5 min providing comparable diagnostic data to standard lengths of acquisition. This may have significant implications for the diagnostic work-up of patients with melanoma, given the need for true whole-body imaging in this type of cancer.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a LAFOV PET/CT
|2 Other
650 _ 7 |a Melanoma
|2 Other
650 _ 7 |a SUV
|2 Other
650 _ 7 |a Total body
|2 Other
650 _ 7 |a Whole-body
|2 Other
650 _ 7 |a [18F]FDG
|2 Other
700 1 _ |a Pan, Leyun
|0 P:(DE-He78)96ac0342a3ccf9553e3d4c9da9b821b0
|b 1
|u dkfz
700 1 _ |a Kopp-Schneider, Annette
|0 P:(DE-He78)bb6a7a70f976eb8df1769944bf913596
|b 2
|u dkfz
700 1 _ |a Weru, Vivienn
|0 P:(DE-He78)7dc85735e114a4ace658ba1450a2cca6
|b 3
|u dkfz
700 1 _ |a Hassel, Jessica C
|b 4
700 1 _ |a Dimitrakopoulou-Strauss, Antonia
|0 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992
|b 5
|e Last author
|u dkfz
773 _ _ |a 10.1007/s00259-022-06070-7
|0 PERI:(DE-600)2098375-X
|n 4
|p 1158-1167
|t European journal of nuclear medicine and molecular imaging
|v 50
|y 2023
|x 1619-7070
909 C O |o oai:inrepo02.dkfz.de:186247
|p VDB
|p OpenAPC
|p openCost
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)96ac0342a3ccf9553e3d4c9da9b821b0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)bb6a7a70f976eb8df1769944bf913596
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)7dc85735e114a4ace658ba1450a2cca6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2022
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2022-11-23
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2022-11-23
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-23
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J NUCL MED MOL I : 2022
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-23
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-23
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR J NUCL MED MOL I : 2022
|d 2023-08-23
915 p c |a APC keys set
|2 APC
|0 PC:(DE-HGF)0000
915 p c |a Local Funding
|2 APC
|0 PC:(DE-HGF)0001
920 2 _ |0 I:(DE-He78)E060-20160331
|k E060
|l E060 KKE Nuklearmedizin
|x 0
920 1 _ |0 I:(DE-He78)E060-20160331
|k E060
|l E060 KKE Nuklearmedizin
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 1
920 0 _ |0 I:(DE-He78)E060-20160331
|k E060
|l E060 KKE Nuklearmedizin
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E060-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED
980 _ _ |a APC

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21